IP Group's Istesso begins new phase in arthritis study
IP Group announced on Tuesday that its majority owned subsidiary Istesso had completed a successful first round of dosing in a Phase 2a study of a potential rheumatoid arthritis drug.
Financial Services
14,584.59
17:15 16/05/24
FTSE 250
20,822.84
17:14 16/05/24
FTSE 350
4,642.54
17:15 16/05/24
FTSE All-Share
4,594.70
16:50 16/05/24
IP Group
52.70p
16:55 16/05/24
The intellectual property developer said the study into the MBS2320 drug would last for 12 weeks and is a randomised, placebo-controlled, double-blind, multi-centre trial which was designed to test the safety, tolerability and efficacy of the drug.
"We are pleased to see MBS2320 progress into Phase 2a, representing a significant developmental milestone for this programme. Istesso is focussed on the rapidly emerging field of immunometabolism, with MBS2320 its lead, first-in-class agent," said Sam Williams, chief executive officer of Istesso.
Further behind MBS2320 in Istesso's pipeline he said there were other assets that work by reprogramming metabolism to treat autoimmune and inflammatory conditions such as multiple sclerosis, psoriasis and ulcerative colitis.
The full results of the arthritis study are expected in late 2018.
As of 0900 BST, shares in IP Group had seen little change, down 0.68% to 132.60p.